4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Entrada Therapeutics, Inc. (TRDA) operates in the Biotechnology industry and is headquartered in Boston, United States with about 152 employees. Its market capitalization is roughly $287 million. In the fiscal year ended 2025-12-31, TRDA reported $25M in revenue and ($144M) in net income.
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.
Interactive charts & full statements → Open the TRDA valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $25M | $211M | $129M | $0M | — |
| Operating Income (EBIT) | ($158M) | $47M | ($3M) | ($97M) | — |
| Net Income | ($144M) | $66M | ($7M) | ($95M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $1M | $1M | $2M | $2M | $21M |
| Operating Income (EBIT) | ($42M) | ($42M) | ($47M) | ($47M) | ($22M) |
| Net Income | ($40M) | ($39M) | ($44M) | ($43M) | ($17M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $377M | $526M | $469M | $252M | — |
| Total Liabilities | $71M | $98M | $227M | $40M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TRDA viewer.
About TickerBase · Data methodology & sources